07:47 AM EDT, 06/13/2024 (MT Newswires) -- Moderna ( MRNA ) said Thursday that mRNA-1283, an investigational next-generation COVID-19 vaccine, met its primary vaccine efficacy endpoint in a phase 3 trial.

The study demonstrated 'non-inferior vaccine efficacy' against COVID-19 compared to Spikevax (mRNA-1273) in about 11,400 participants aged 12 years and older.

The company said it observed higher efficacy in adults of 18 years and older compared to Spikevax.

The company further said it found mRNA-1283 to have a similar safety profile to Spikevax, and the most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.

Price: 147.00, Change: -0.72, Percent Change: -0.49